Marketdash
Back to News

Darden Restaurants Reveals GLP-1 Weight Loss Drugs Are Changing How Much Customers Drink

MarketDash Editorial Team
10 hours ago
Darden Restaurants beat sales expectations and raised its revenue outlook, but executives revealed they're tracking an unexpected side effect of obesity drugs: customers on GLP-1 medications are ordering less alcohol at Olive Garden and LongHorn Steakhouse.

Darden Restaurants, Inc. (DRI) shares climbed Thursday after the restaurant giant delivered strong second-quarter results and raised its sales outlook for the year. But buried in the earnings call was a fascinating tidbit about modern medicine intersecting with dinner plans: obesity drugs like GLP-1 are changing what customers order, and Darden is paying attention.

The Numbers Look Pretty Good

Darden reported second-quarter adjusted earnings per share of $2.08, just shy of the analyst consensus estimate of $2.10. Not a disaster by any stretch. More importantly, quarterly sales hit $3.102 billion, climbing 7.3% year over year and beating the Street's expectation of $3.071 billion.

The sales growth came from a blended same-restaurant sales increase of 4.3% combined with 30 net new restaurant openings. That same-restaurant sales number is the one Wall Street really cares about because it strips out the effect of simply opening more locations.

Breaking it down by brand, Olive Garden posted a 4.7% same-restaurant sales increase. LongHorn Steakhouse did even better at 5.9%. The Fine Dining segment grew a modest 0.8%, while Other Business units gained 3.1%.

In dollar terms, Olive Garden pulled in $1.362 billion for the quarter, up from $1.292 billion a year ago. LongHorn Steakhouse sales rose to $775.9 million from $710.1 million.

"Our restaurant teams did a great job of being brilliant with the basics, driving record, or near-record, guest satisfaction scores across all our brands," said Darden President and CEO Rick Cardenas.

The GLP-1 Factor

Here's where it gets interesting. During the earnings conference call, executives addressed shifting consumer behavior and specifically mentioned they're monitoring the impact of GLP-1 usage, particularly on alcohol consumption. These weight loss medications, which include drugs like Ozempic and Wegovy, have been known to reduce appetite and cravings, and apparently that extends to alcoholic beverages.

Darden highlighted that lighter-portion menu options are helping offset those changes. So while some customers might be drinking less, the company is adapting by offering food options that appeal to people who are more conscious about portion sizes.

What Else Came Up on the Call

Management shared that the company saw record Thanksgiving reservations across its brands, with holiday bookings tracking strong heading into the year-end period. That's a good sign for near-term momentum.

On the cost side, pricing trends have begun to improve in recent weeks, allowing Darden to take some pricing coverage in the back half of the fiscal year. The gap between pricing and inflation is expected to narrow by about half by the third quarter.

Beef costs remain a headache and are expected to stay elevated into the third quarter, with some relief anticipated in the fourth quarter. Despite those ongoing cost pressures, management said it expects fiscal third-quarter earnings per share to grow in the mid-single-digit range compared with last year.

"Despite facing significant commodity headwinds, we leveraged our four competitive advantages to provide strong value for our guests and we made appropriate investments in the business to ensure long-term success," Cardenas added.

Looking ahead, Darden acknowledged some macro uncertainty in the first half of the year but pointed to a potential boost to consumer spending from fiscal stimulus expected in early 2026.

Capital Allocation and Outlook

Darden's board declared a quarterly cash dividend of $1.50 per share, payable Feb. 2, 2026, to shareholders of record as of Jan. 9, 2026. The company also repurchased about 1.1 million shares for $222 million during the quarter, leaving $643 million remaining under its $1 billion authorization.

For the full fiscal year 2026, Darden reaffirmed its adjusted EPS outlook of $10.50 to $10.70, which lines up with the analyst consensus estimate of $10.60. The company expects total sales growth of 8.5% to 9.3%, including about 2% from a 53rd week in the fiscal calendar. Same-restaurant sales growth is projected at 3.5% to 4.3%.

Darden raised its fiscal 2026 sales outlook to a range of $13.104 billion to $13.200 billion, up from the prior forecast of $12.983 billion to $13.104 billion and above the Street estimate of $13.071 billion. The company plans to open 65 to 70 new restaurants this year.

DRI Price Action: Darden Restaurants shares were up 1.51% at $192.39 at the time of publication on Thursday.

Back to News

Darden Restaurants Reveals GLP-1 Weight Loss Drugs Are Changing How Much Customers Drink

MarketDash Editorial Team
10 hours ago
Darden Restaurants beat sales expectations and raised its revenue outlook, but executives revealed they're tracking an unexpected side effect of obesity drugs: customers on GLP-1 medications are ordering less alcohol at Olive Garden and LongHorn Steakhouse.

Darden Restaurants, Inc. (DRI) shares climbed Thursday after the restaurant giant delivered strong second-quarter results and raised its sales outlook for the year. But buried in the earnings call was a fascinating tidbit about modern medicine intersecting with dinner plans: obesity drugs like GLP-1 are changing what customers order, and Darden is paying attention.

The Numbers Look Pretty Good

Darden reported second-quarter adjusted earnings per share of $2.08, just shy of the analyst consensus estimate of $2.10. Not a disaster by any stretch. More importantly, quarterly sales hit $3.102 billion, climbing 7.3% year over year and beating the Street's expectation of $3.071 billion.

The sales growth came from a blended same-restaurant sales increase of 4.3% combined with 30 net new restaurant openings. That same-restaurant sales number is the one Wall Street really cares about because it strips out the effect of simply opening more locations.

Breaking it down by brand, Olive Garden posted a 4.7% same-restaurant sales increase. LongHorn Steakhouse did even better at 5.9%. The Fine Dining segment grew a modest 0.8%, while Other Business units gained 3.1%.

In dollar terms, Olive Garden pulled in $1.362 billion for the quarter, up from $1.292 billion a year ago. LongHorn Steakhouse sales rose to $775.9 million from $710.1 million.

"Our restaurant teams did a great job of being brilliant with the basics, driving record, or near-record, guest satisfaction scores across all our brands," said Darden President and CEO Rick Cardenas.

The GLP-1 Factor

Here's where it gets interesting. During the earnings conference call, executives addressed shifting consumer behavior and specifically mentioned they're monitoring the impact of GLP-1 usage, particularly on alcohol consumption. These weight loss medications, which include drugs like Ozempic and Wegovy, have been known to reduce appetite and cravings, and apparently that extends to alcoholic beverages.

Darden highlighted that lighter-portion menu options are helping offset those changes. So while some customers might be drinking less, the company is adapting by offering food options that appeal to people who are more conscious about portion sizes.

What Else Came Up on the Call

Management shared that the company saw record Thanksgiving reservations across its brands, with holiday bookings tracking strong heading into the year-end period. That's a good sign for near-term momentum.

On the cost side, pricing trends have begun to improve in recent weeks, allowing Darden to take some pricing coverage in the back half of the fiscal year. The gap between pricing and inflation is expected to narrow by about half by the third quarter.

Beef costs remain a headache and are expected to stay elevated into the third quarter, with some relief anticipated in the fourth quarter. Despite those ongoing cost pressures, management said it expects fiscal third-quarter earnings per share to grow in the mid-single-digit range compared with last year.

"Despite facing significant commodity headwinds, we leveraged our four competitive advantages to provide strong value for our guests and we made appropriate investments in the business to ensure long-term success," Cardenas added.

Looking ahead, Darden acknowledged some macro uncertainty in the first half of the year but pointed to a potential boost to consumer spending from fiscal stimulus expected in early 2026.

Capital Allocation and Outlook

Darden's board declared a quarterly cash dividend of $1.50 per share, payable Feb. 2, 2026, to shareholders of record as of Jan. 9, 2026. The company also repurchased about 1.1 million shares for $222 million during the quarter, leaving $643 million remaining under its $1 billion authorization.

For the full fiscal year 2026, Darden reaffirmed its adjusted EPS outlook of $10.50 to $10.70, which lines up with the analyst consensus estimate of $10.60. The company expects total sales growth of 8.5% to 9.3%, including about 2% from a 53rd week in the fiscal calendar. Same-restaurant sales growth is projected at 3.5% to 4.3%.

Darden raised its fiscal 2026 sales outlook to a range of $13.104 billion to $13.200 billion, up from the prior forecast of $12.983 billion to $13.104 billion and above the Street estimate of $13.071 billion. The company plans to open 65 to 70 new restaurants this year.

DRI Price Action: Darden Restaurants shares were up 1.51% at $192.39 at the time of publication on Thursday.